To determine the efficacy of a 12-week supervised, hypertrophy-oriented strength training program in preserving skeletal muscle mass, physical function, and quality of life in patients with unresectable pancreatic cancer compared to standard care.

Two-arm randomized controlled trial will recruit patients with unresectable pancreatic cancer undergoing chemotherapy. Participants will be randomized (1:1) to an Intervention Group (resistance training twice weekly) or a Control Group (standard care). The primary outcome is the change in total lean body mass (assessed by DXA) at week 12. Secondary outcomes include maximal strength, peak power, cardiorespiratory capacity, and patient-reported measures.

Inclusion Criteria:

• Diagnosis of locally advanced or metastatic unresectable pancreatic cancer
• Undergoing chemotherapy or immunotherapy treatment
• Age ≥ 18 years
• ECOG score ≤ 2

Exclusion Criteria:

• Any relative or absolute contraindication that prevents the performance of training or physical tests.
• Diagnosis of other types of primary cancer
• Inability to understand Spanish for proper comprehension of the informed consent and questionnaires

Data will be available, including de-identified individual participant data, data dictionaries, and study protocols.

Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.

Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact investigacion@universidadeuropea.es